Disease · MONDO_0005542

acute coronary syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute coronary syndrome. Diseases, record MONDO_0005542. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005542

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute coronary syndrome; Open Targets
Open Targets ID: MONDO_0005542; Open Targets
MeSH: D054058; MeSH
NCI Thesaurus: C53652; NCI Thesaurus
Highest stage of its drugs: Approval, for 12 of its 83 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs83

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TICAGRELOR	CHEMBL398435	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	103	98	98	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Approval	EMA Human Drugs	109	88	88	Drugs and targets
PRASUGREL	CHEMBL1201772	Small molecule	Approval	EMA Human Drugs and TTD	52	49	49	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Approval	EMA Human Drugs and PMDA	41	34	34	Drugs and targets
RIVAROXABAN	CHEMBL198362	Small molecule	Approval	EMA Human Drugs	8	6	6	Drugs and targets
CANGRELOR	CHEMBL334966	Small molecule	Approval	EMA Human Drugs	4	3	3	Drugs and targets
EPTIFIBATIDE	CHEMBL1174	Protein	Approval	DailyMed	4	3	3	Drugs and targets
TIROFIBAN	CHEMBL916	Small molecule	Approval	TTD	4	3	3	Drugs and targets
BIVALIRUDIN	CHEMBL5314348	Protein	Approval	EMA Human Drugs, at withdrawal	3	2	2	Drugs and targets
CLOPIDOGREL BISULFATE	CHEMBL1083385	Small molecule	Approval	DailyMed and PMDA	65	1	1	Drugs and targets

1 to 10 of 83

See all 83 drugs

Targets109

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
P2RY12	P2Y purinoceptor 12	6	Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor; Purinergic receptor P2Y12 negative allosteric modulator	Approval	https://conductscience.org/library/genes/64805	Drugs and targets
SERPINC1	Antithrombin-III	5	Antithrombin-III activator	Phase 3	https://conductscience.org/library/genes/462	Drugs and targets
PCSK9	PCSK9 mRNA	4	PCSK9 mRNA RNAi inhibitor; Subtilisin/kexin type 9 inhibitor	Phase 3	https://conductscience.org/library/genes/255738	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	3	Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
F10	Coagulation factor X	3	Coagulation factor X inhibitor	Approval	https://conductscience.org/library/genes/2159	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	3	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
ACE	Angiotensin-converting enzyme	2	Angiotensin-converting enzyme inhibitor	Phase 3	https://conductscience.org/library/genes/1636	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	2	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Phase 3	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	2	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Phase 3	https://conductscience.org/library/genes/1141	Drugs and targets
F2R	Proteinase-activated receptor 1	2	Proteinase-activated receptor 1 antagonist; Proteinase-activated receptor 1 inhibitor	Phase 2	https://conductscience.org/library/genes/2149	Drugs and targets

1 to 10 of 109

See all 109 targets

Trials237

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00202878	IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)	Phase 3	18,144	2015-09-30	Hypercholesterolemia, Myocardial Infarction	EZETIMIBE, SIMVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00097591	A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention	Phase 3	13,619	2010-09-16	Coronary Arteriosclerosis, Acute Coronary Syndromes	CLOPIDOGREL, PRASUGREL	Its record names the disease	ClinicalTrials.gov
NCT00089895	EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)	Phase 3	9,406	2009-12-21	Myocardial Ischemia, Acute Coronary Syndrome	EPTIFIBATIDE	Its record names the disease	ClinicalTrials.gov
NCT00305162	A Clinical Trial to Demonstrate the Efficacy of Cangrelor	Phase 3	8,882	2014-04-23	Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)	CANGRELOR, CLOPIDOGREL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03381742	Efficacy and Safety of Low-dose Ticagrelor	Phase 2/3	3,043	2019-09-30	Coronary Artery Disease	CLOPIDOGREL, TICAGRELOR	Open Targets' reading of its record	ClinicalTrials.gov
NCT02293395	A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome	Phase 2	3,037	2017-11-13	Acute Coronary Syndrome	ASPIRIN, CLOPIDOGREL, RIVAROXABAN, TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT01087723	European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial	Phase 3	2,198	2016-02-12	Acute Coronary Syndrome	BIVALIRUDIN, HEPARIN	Its record names the disease	ClinicalTrials.gov
NCT01870921	Brilinta DaYu Study	Phase 4	2,004	2016-11-09	Acute Coronary Syndrome	TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT00409578	Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome	Phase 2	1,101	2011-02-02	Post Acute Coronary Syndrome, Myocardial Ischemia	ALISKIREN, VALSARTAN	Its record names the disease	ClinicalTrials.gov
NCT00091507	IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.	Phase 3	911	2013-01-30	Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction, Heart Failure, Congestive	DEXTROSE, INSULIN HUMAN, POTASSIUM	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov

1 to 10 of 237

See all 237 trials

Comparisons in its trials64

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ezetimide/Simvastatin vs Simvastatin: serious adverse events	3,640 of 9,067	3,649 of 9,077	18,144	NCT00202878	Trial comparisons
Prasugrel vs Clopidogrel: Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events	797 of 6,813	938 of 6,795	13,608	NCT00097591	Trial comparisons
Prasugrel vs Clopidogrel: Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke	692 of 6,813	822 of 6,795	13,608	NCT00097591	Trial comparisons
Prasugrel vs Clopidogrel: serious adverse events	1,731 of 6,741	1,675 of 6,716	13,457	NCT00097591	Trial comparisons
Eptifibatide vs Placebo: serious adverse events	66 of 4,686	60 of 4,643	9,329	NCT00089895	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding	19 of 4,374	14 of 4,365	8,739	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of GUSTO Severe / Life-threatening Bleeding	10 of 4,374	11 of 4,365	8,739	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of ACUITY Major Bleeding	151 of 4,374	120 of 4,365	8,739	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of ACUITY Major Bleeding (Without Hematoma >/= 5 cm)	78 of 4,374	65 of 4,365	8,739	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: serious adverse events	125 of 4,374	127 of 4,365	8,739	NCT00305162	Trial comparisons

1 to 10 of 64

See all 64 comparisons in its trials

Papers from its trials361

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40014670	RESULT	1	PubMed
38887886	RESULT	1	PubMed
33028101	RESULT	1	PubMed
31475799	RESULT	2	PubMed
30166073	RESULT	1	PubMed
30127210	RESULT	1	PubMed
29930021	RESULT	1	PubMed
29878086	RESULT	1	PubMed
29622563	RESULT	1	PubMed
29622168	RESULT	2	PubMed

1 to 10 of 361

See all 361 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005542

GET https://conductscience.org/api/diseases/v1/MONDO_0005542/drugs?page=2

API reference For AI assistants